Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer.

Du T, Sikora MJ, Levine KM, Tasdemir N, Riggins RB, Wendell SG, Van Houten B, Oesterreich S.

Breast Cancer Res. 2018 Sep 4;20(1):106. doi: 10.1186/s13058-018-1041-8.

2.

Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma.

Tiek DM, Rone JD, Graham GT, Pannkuk EL, Haddad BR, Riggins RB.

Sci Rep. 2018 May 8;8(1):7222. doi: 10.1038/s41598-018-25588-1.

3.

The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer.

Fernandez HR, Gadre SM, Tan M, Graham GT, Mosaoa R, Ongkeko MS, Kim KA, Riggins RB, Parasido E, Petrini I, Pacini S, Cheema A, Varghese R, Ressom HW, Zhang Y, Albanese C, Üren A, Paige M, Giaccone G, Avantaggiati ML.

Cell Death Differ. 2018 Jul;25(7):1239-1258. doi: 10.1038/s41418-018-0101-z. Epub 2018 Apr 12.

4.

RNA Interference Screening to Identify Proliferation Determinants in Breast Cancer Cells.

Zhang YW, Nasto RE, Jablonski SA, Serebriiskii IG, Surana R, Murray J, Johnson M, Riggins RB, Clarke R, Golemis EA, Weiner LM.

Bio Protoc. 2017;7(15). pii: e2435. doi: 10.21769/BioProtoc.2435. Epub 2017 Aug 5.

5.

Differential prioritization of therapies to subtypes of triple negative breast cancer using a systems medicine method.

Wathieu H, Issa NT, Fernandez AI, Mohandoss M, Tiek DM, Franke JL, Byers SW, Riggins RB, Dakshanamurthy S.

Oncotarget. 2017 Oct 9;8(54):92926-92942. doi: 10.18632/oncotarget.21669. eCollection 2017 Nov 3.

6.

Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities.

Stires H, Heckler MM, Fu X, Li Z, Grasso CS, Quist MJ, Lewis JA, Klimach U, Zwart A, Mahajan A, Győrffy B, Cavalli LR, Riggins RB.

Mol Cell Endocrinol. 2018 Aug 15;471:105-117. doi: 10.1016/j.mce.2017.09.024. Epub 2017 Sep 19.

7.

Estrogen-related receptor β (ERRβ) - renaissance receptor or receptor renaissance?

Divekar SD, Tiek DM, Fernandez A, Riggins RB.

Nucl Recept Signal. 2016 Jun 21;14:e002. doi: 10.1621/nrs.14002. eCollection 2016. Review.

8.

Antimitotic activity of DY131 and the estrogen-related receptor beta 2 (ERRβ2) splice variant in breast cancer.

Heckler MM, Zeleke TZ, Divekar SD, Fernandez AI, Tiek DM, Woodrick J, Farzanegan A, Roy R, Üren A, Mueller SC, Riggins RB.

Oncotarget. 2016 Jul 26;7(30):47201-47220. doi: 10.18632/oncotarget.9719.

9.

ERRγ target genes are poor prognostic factors in Tamoxifen-treated breast cancer.

Madhavan S, Gusev Y, Singh S, Riggins RB.

J Exp Clin Cancer Res. 2015 May 15;34:45. doi: 10.1186/s13046-015-0150-9.

10.

Interferon regulatory factor-1 signaling regulates the switch between autophagy and apoptosis to determine breast cancer cell fate.

Schwartz-Roberts JL, Cook KL, Chen C, Shajahan-Haq AN, Axelrod M, Wärri A, Riggins RB, Jin L, Haddad BR, Kallakury BV, Baumann WT, Clarke R.

Cancer Res. 2015 Mar 15;75(6):1046-55. doi: 10.1158/0008-5472.CAN-14-1851. Epub 2015 Jan 9.

11.

ERRβ splice variants differentially regulate cell cycle progression.

Heckler MM, Riggins RB.

Cell Cycle. 2015;14(1):31-45. doi: 10.4161/15384101.2014.972886.

12.

NF-κB signaling is required for XBP1 (unspliced and spliced)-mediated effects on antiestrogen responsiveness and cell fate decisions in breast cancer.

Hu R, Warri A, Jin L, Zwart A, Riggins RB, Fang HB, Clarke R.

Mol Cell Biol. 2015 Jan;35(2):379-90. doi: 10.1128/MCB.00847-14. Epub 2014 Nov 3.

13.

ERK/MAPK regulates ERRγ expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer.

Heckler MM, Thakor H, Schafer CC, Riggins RB.

FEBS J. 2014 May;281(10):2431-42. doi: 10.1111/febs.12797. Epub 2014 Apr 28.

14.

Reconstruction of transcriptional regulatory networks by stability-based network component analysis.

Chen X, Xuan J, Wang C, Shajahan AN, Riggins RB, Clarke R.

IEEE/ACM Trans Comput Biol Bioinform. 2013 Nov-Dec;10(6):1347-58. doi: 10.1109/TCBB.2012.146.

15.
16.

In silico discovery of mitosis regulation networks associated with early distant metastases in estrogen receptor positive breast cancers.

Gusev Y, Riggins RB, Bhuvaneshwar K, Gauba R, Sheahan L, Clarke R, Madhavan S.

Cancer Inform. 2013;12:31-51. doi: 10.4137/CIN.S10329. Epub 2013 Feb 13.

17.

Identifying protein interaction subnetworks by a bagging Markov random field-based method.

Chen L, Xuan J, Riggins RB, Wang Y, Clarke R.

Nucleic Acids Res. 2013 Jan;41(2):e42. doi: 10.1093/nar/gks951. Epub 2012 Nov 17.

18.

Trans-resveratrol boronic acid exhibits enhanced anti-proliferative activity on estrogen-dependent MCF-7 breast cancer cells.

Yenugonda VM, Kong Y, Deb TB, Yang Y, Riggins RB, Brown ML.

Cancer Biol Ther. 2012 Aug;13(10):925-34. doi: 10.4161/cbt.20845. Epub 2012 Aug 1.

19.

Robust identification of transcriptional regulatory networks using a Gibbs sampler on outlier sum statistic.

Gu J, Xuan J, Riggins RB, Chen L, Wang Y, Clarke R.

Bioinformatics. 2012 Aug 1;28(15):1990-7. doi: 10.1093/bioinformatics/bts296. Epub 2012 May 17. Erratum in: Bioinformatics. 2014 Aug 1;30(15):2242.

20.

Identifying cancer biomarkers by network-constrained support vector machines.

Chen L, Xuan J, Riggins RB, Clarke R, Wang Y.

BMC Syst Biol. 2011 Oct 12;5:161. doi: 10.1186/1752-0509-5-161.

21.

G-DOC: a systems medicine platform for personalized oncology.

Madhavan S, Gusev Y, Harris M, Tanenbaum DM, Gauba R, Bhuvaneshwar K, Shinohara A, Rosso K, Carabet LA, Song L, Riggins RB, Dakshanamurthy S, Wang Y, Byers SW, Clarke R, Weiner LM.

Neoplasia. 2011 Sep;13(9):771-83.

22.

Motif-guided sparse decomposition of gene expression data for regulatory module identification.

Gong T, Xuan J, Chen L, Riggins RB, Li H, Hoffman EP, Clarke R, Wang Y.

BMC Bioinformatics. 2011 Mar 22;12:82. doi: 10.1186/1471-2105-12-82.

23.

Endoplasmic reticulum stress, the unfolded protein response, and gene network modeling in antiestrogen resistant breast cancer.

Clarke R, Shajahan AN, Wang Y, Tyson JJ, Riggins RB, Weiner LM, Bauman WT, Xuan J, Zhang B, Facey C, Aiyer H, Cook K, Hickman FE, Tavassoly I, Verdugo A, Chen C, Zwart A, Wärri A, Hilakivi-Clarke LA.

Horm Mol Biol Clin Investig. 2011 Mar;5(1):35-44.

24.

Orphan nuclear receptors in breast cancer pathogenesis and therapeutic response.

Riggins RB, Mazzotta MM, Maniya OZ, Clarke R.

Endocr Relat Cancer. 2010 Aug 16;17(3):R213-31. doi: 10.1677/ERC-10-0058. Print 2010 Sep. Review.

25.

IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-kappaB, BCL2 family members, and signaling to caspase-dependent apoptosis.

Ning Y, Riggins RB, Mulla JE, Chung H, Zwart A, Clarke R.

Mol Cancer Ther. 2010 May;9(5):1274-85. doi: 10.1158/1535-7163.MCT-09-1169.

26.

Multilevel support vector regression analysis to identify condition-specific regulatory networks.

Chen L, Xuan J, Riggins RB, Wang Y, Hoffman EP, Clarke R.

Bioinformatics. 2010 Jun 1;26(11):1416-22. doi: 10.1093/bioinformatics/btq144. Epub 2010 Apr 7.

27.

BCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells.

Nehra R, Riggins RB, Shajahan AN, Zwart A, Crawford AC, Clarke R.

FASEB J. 2010 Jun;24(6):2040-55. doi: 10.1096/fj.09-138305. Epub 2010 Feb 12.

28.

Co-inhibition of BCL-W and BCL2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis.

Crawford AC, Riggins RB, Shajahan AN, Zwart A, Clarke R.

PLoS One. 2010 Jan 6;5(1):e8604. doi: 10.1371/journal.pone.0008604.

29.

Identification of condition-specific regulatory modules through multi-level motif and mRNA expression analysis.

Chen L, Xuan J, Wang Y, Hoffman EP, Riggins RB, Clarke R.

Int J Comput Biol Drug Des. 2009;2(1):1-20.

30.

Frequent loss of heterozygosity at the interferon regulatory factor-1 gene locus in breast cancer.

Cavalli LR, Riggins RB, Wang A, Clarke R, Haddad BR.

Breast Cancer Res Treat. 2010 May;121(1):227-31. doi: 10.1007/s10549-009-0509-8. Epub 2009 Aug 21.

31.

The role of X-box binding protein-1 in tumorigenicity.

Shajahan AN, Riggins RB, Clarke R.

Drug News Perspect. 2009 Jun;22(5):241-6. doi: 10.1358/dnp.2009.22.5.1378631. Review.

32.

Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells.

Clarke R, Shajahan AN, Riggins RB, Cho Y, Crawford A, Xuan J, Wang Y, Zwart A, Nehra R, Liu MC.

J Steroid Biochem Mol Biol. 2009 Mar;114(1-2):8-20.

33.

Differential dependency network analysis to identify condition-specific topological changes in biological networks.

Zhang B, Li H, Riggins RB, Zhan M, Xuan J, Zhang Z, Hoffman EP, Clarke R, Wang Y.

Bioinformatics. 2009 Feb 15;25(4):526-32. doi: 10.1093/bioinformatics/btn660. Epub 2008 Dec 26.

34.

ERRgamma mediates tamoxifen resistance in novel models of invasive lobular breast cancer.

Riggins RB, Lan JP, Zhu Y, Klimach U, Zwart A, Cavalli LR, Haddad BR, Chen L, Gong T, Xuan J, Ethier SP, Clarke R.

Cancer Res. 2008 Nov 1;68(21):8908-17. doi: 10.1158/0008-5472.CAN-08-2669. Erratum in: Cancer Res. 2009 Feb 15;69(4):1695. Zhu, Yuelin [added].

35.

Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines.

Gomez BP, Riggins RB, Shajahan AN, Klimach U, Wang A, Crawford AC, Zhu Y, Zwart A, Wang M, Clarke R.

FASEB J. 2007 Dec;21(14):4013-27. Epub 2007 Jul 27.

PMID:
17660348
36.
37.

The A4396G polymorphism in interferon regulatory factor 1 is frequently expressed in breast cancer cell lines.

Bouker KB, Skaar TC, Harburger DS, Riggins RB, Fernandez DR, Zwart A, Clarke R.

Cancer Genet Cytogenet. 2007 May;175(1):61-4.

PMID:
17498560
38.

Pathways to tamoxifen resistance.

Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH.

Cancer Lett. 2007 Oct 18;256(1):1-24. Epub 2007 May 1. Review.

39.

Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b.

Riggins RB, Thomas KS, Ta HQ, Wen J, Davis RJ, Schuh NR, Donelan SS, Owen KA, Gibson MA, Shupnik MA, Silva CM, Parsons SJ, Clarke R, Bouton AH.

Cancer Res. 2006 Jul 15;66(14):7007-15.

40.

Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer.

Riggins RB, Bouton AH, Liu MC, Clarke R.

Vitam Horm. 2005;71:201-37. Review.

PMID:
16112269
41.

Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis.

Bouker KB, Skaar TC, Riggins RB, Harburger DS, Fernandez DR, Zwart A, Wang A, Clarke R.

Carcinogenesis. 2005 Sep;26(9):1527-35. Epub 2005 May 5.

PMID:
15878912
43.

interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (faslodex, fulvestrant).

Bouker KB, Skaar TC, Fernandez DR, O'Brien KA, Riggins RB, Cao D, Clarke R.

Cancer Res. 2004 Jun 1;64(11):4030-9.

44.

Synergistic promotion of c-Src activation and cell migration by Cas and AND-34/BCAR3.

Riggins RB, Quilliam LA, Bouton AH.

J Biol Chem. 2003 Jul 25;278(30):28264-73. Epub 2003 May 11.

45.

Src-dependent association of Cas and p85 phosphatidylinositol 3'-kinase in v-crk-transformed cells.

Riggins RB, DeBerry RM, Toosarvandani MD, Bouton AH.

Mol Cancer Res. 2003 Apr;1(6):428-37.

46.

Functions of the adapter protein Cas: signal convergence and the determination of cellular responses.

Bouton AH, Riggins RB, Bruce-Staskal PJ.

Oncogene. 2001 Oct 1;20(44):6448-58. Review.

Supplemental Content

Loading ...
Support Center